Krilogy Financial LLC Takes $731,000 Position in AstraZeneca PLC $AZN

Krilogy Financial LLC purchased a new stake in AstraZeneca PLC (NASDAQ:AZN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 9,003 shares of the company’s stock, valued at approximately $731,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. NewSquare Capital LLC grew its position in AstraZeneca by 149.3% in the second quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock worth $25,000 after acquiring an additional 218 shares in the last quarter. Rakuten Investment Management Inc. acquired a new stake in shares of AstraZeneca in the 3rd quarter valued at $31,000. E Fund Management Hong Kong Co. Ltd. boosted its holdings in AstraZeneca by 144.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock worth $36,000 after purchasing an additional 275 shares in the last quarter. VSM Wealth Advisory LLC bought a new stake in AstraZeneca in the second quarter worth $33,000. Finally, FSA Wealth Management LLC increased its position in AstraZeneca by 376.0% during the second quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock worth $33,000 after buying an additional 376 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

Shares of AstraZeneca stock opened at $205.47 on Friday. The firm has a market cap of $318.66 billion, a P/E ratio of 68.26, a price-to-earnings-growth ratio of 1.59 and a beta of 0.34. The firm’s 50-day simple moving average is $112.72 and its 200-day simple moving average is $92.82. AstraZeneca PLC has a twelve month low of $122.48 and a twelve month high of $206.71. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.69 and a current ratio of 0.88.

AstraZeneca Dividend Announcement

The firm also recently announced a dividend, which will be paid on Monday, March 23rd. Stockholders of record on Friday, February 20th will be issued a $1.595 dividend. This represents a dividend yield of 165.0%. The ex-dividend date of this dividend is Friday, February 20th. AstraZeneca’s payout ratio is presently 34.77%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on AZN shares. Jefferies Financial Group assumed coverage on AstraZeneca in a research note on Monday, October 27th. They issued a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of AstraZeneca in a research report on Friday, February 6th. HSBC reaffirmed a “buy” rating and set a $108.00 price objective on shares of AstraZeneca in a report on Wednesday, December 10th. Guggenheim reiterated a “buy” rating on shares of AstraZeneca in a report on Wednesday, December 3rd. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, January 21st. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, AstraZeneca has an average rating of “Moderate Buy” and an average target price of $95.75.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.